Dpp4 Inhibitor Sitagliptin As A Potential Treatment Option In Metformin-Intolerant Obese Women With Polycystic Ovary Syndrome: A Pilot Randomized Study
Authors:
- 1 January 2018
- journal article
- research article
- Published by Elsevier in Endocrine Practice
- Vol. 24 (1) , 69-77
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Insulin Secretion and Its Determinants in the Progression of Impaired Glucose Tolerance to Type 2 Diabetes in Impaired Glucose-Tolerant IndividualsDiabetes Care, 2012
- Should all women with PCOS be treated for insulin resistance?Fertility and Sterility, 2012
- Dipeptidyl peptidase‐4 inhibitors and preservation of pancreatic islet‐cell function: a critical appraisal of the evidenceDiabetes, Obesity and Metabolism, 2011
- When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?Clinical Endocrinology, 2011
- Review: Role of metformin in the management of polycystic ovary syndromeTherapeutic Advances in Endocrinology and Metabolism, 2010
- The effect of DPP‐4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucoseClinical Endocrinology, 2010
- Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experienceVascular Health and Risk Management, 2010
- Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistanceEuropean Journal of Endocrinology, 2007
- Exercise as a therapeutic intervention for the prevention and treatment of insulin resistanceDiabetes/Metabolism Research and Reviews, 2004
- Exercise and Insulin Sensitivity: A ReviewInternational Journal of Sports Medicine, 2000